The Avicena Group, Inc. – Product Pipeline Review – H2 2011

The Avicena Group, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “The Avicena Group, Inc. – Product Pipeline Review – H2 2011” provides data on the The Avicena Group, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, The Avicena Group, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from The Avicena Group, Inc. and industry–specific third party sources, put together by Global Markets Direct’s team.

Scope

• The Avicena Group, Inc.
• Brief The Avicena Group, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
• Review of current pipeline of The Avicena Group, Inc. human therapeutic division.
• Overview of pipeline therapeutics across various therapy areas.
• Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
• Product profiles for late stage and clinical stage products of The Avicena Group, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
• Recent updates of the The Avicena Group, Inc.’s pipeline in the last quarter.
• Key discontinued and dormant projects.
• Latest news and deals relating to the products.

Reasons to buy

• Evaluate The Avicena Group, Inc.’s strategic position with total access to detailed information on its product pipeline.
• Assess the growth potential of The Avicena Group, Inc. in its therapy areas of focus.
• Identify new drug targets and therapeutic classes in the The Avicena Group, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
• Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
• Exploit collaboration and partnership opportunities with The Avicena Group, Inc..
• Avoid Intellectual Property Rights related issues.
• Explore the dormant and discontinued projects of The Avicena Group, Inc. and identify potential opportunities in those areas.

Contents

The Avicena Group, Inc. Snapshot
The Avicena Group, Inc. Overview
Key Information
Key Facts
The Avicena Group, Inc. – Research and Development Overview
Key Therapeutic Areas
The Avicena Group, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
The Avicena Group, Inc. – Pipeline Products Glance
The Avicena Group, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
The Avicena Group, Inc. – Drug Profiles
ALS-02
Product Description
Mechanism of Action
R&D Progress
HD-02
Product Description
Mechanism of Action
R&D Progress
The Avicena Group, Inc. – Pipeline Analysis
The Avicena Group, Inc. – Pipeline Products by Therapeutic Class
The Avicena Group, Inc. - Pipeline Products By Target
The Avicena Group, Inc. – Pipeline Products by Route of Administration
The Avicena Group, Inc. – Pipeline Products by Molecule Type
The Avicena Group, Inc. - Dormant Projects
The Avicena Group, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
May 25, 2007: Avicena Highlights Key Collaborators In Amyotrophic Lateral Sclerosis (ALS) Dose Escalation Study Of ALS-02
Jan 24, 2006: Avicena's HD-02 Demonstrates Potential In Treatment Of Huntington's Disease
Mar 23, 2007: Avicena Clarifies Description Of Creatine Versus PD-02
Mar 22, 2007: Avicena Announces Patient Enrollment In National Institutes Of Health (NIH) Phase III Parkinson's Disease Trial
Nov 20, 2007: Data On Avicena's Drug Candidate HD-02 Presented At The 2007 World Congress On Huntington's Disease
Oct 19, 2006: Avicena Announces Completion Of Patient Enrollment For The First Stage Of ALS-08 Phase II Clinical Trial For ALS
Oct 19, 2006: Avicena Announces Completion Of Patient Enrollment For The First Stage Of ALS-08 Phase II Clinical Trial For ALS
Jul 18, 2007: Avicena To Proceed To Confirmatory Phase III Amyotrophic Lateral Sclerosis (ALS) Trial Of ALS-02
Nov 17, 2006: Avicena Completes Patient Enrollment For ALS-08 Phase II Clinical Trial
Jul 16, 2007: Patient Enrollment On Target In National Institutes Of Health Phase III Parkinson's Disease Trial
May 14, 2007: Avicena Initiates Phase I Clinical Trial in Amyotrophic Lateral Sclerosis (ALS)
Mar 14, 2006: Avicena Announces Promising Phase II Results From Parkinson's Disease Trial
Jan 13, 2007: Avicena Advances Clinical Development Of HD-02 For Neurodegenerative Disease
Mar 12, 2008: Avicena's HD-02 To Proceed To NIH Sponsored Phase III Huntington's Disease Trial
May 11, 2006: Avicena Announces Phase III ALS Trial Results Of ALS-02
Dec 06, 2006: Avicena Signs Agreement With The National Institute Of Neurological Disorders And Stroke For Phase III Trial For Novel Parkinson's Disease Candidate
Jul 06, 2006: Avicena Initiates Study Of Combination Therapies For Amyotrophic Lateral Sclerosis
Feb 05, 2007: Avicena Completes Dose-Escalation Portion Of Chronic Toxicology Study Of Parkinson's Disease Drug Candidate PD-02
Dec 03, 2007: Avicena Announces Positive Phase II Data For A Combination Trial Involving AL-08 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)
Dec 03, 2007: Avicena Announces Positive Phase II Data For A Combination Trial Involving AL-08 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)
Dec 03, 2007: Avicena Announces Positive Phase II Data For A Combination Trial Involving AL-08 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

The Avicena Group, Inc. – Pipeline by Therapy Area and Indication, H2 2011
The Avicena Group, Inc. – Pipeline by Stage of Development, H2 2011
The Avicena Group, Inc. – Monotherapy Products in Pipeline, H2 2011
The Avicena Group, Inc. – Phase III, H2 2011
The Avicena Group, Inc. - Pipeline By Therapeutic Class, H2 2011
The Avicena Group, Inc. - Pipeline By Target, H2 2011
The Avicena Group, Inc. – Pipeline By Route of Administration, H2 2011
The Avicena Group, Inc. – Pipeline By Molecule Type, H2 2011
The Avicena Group, Inc. - Dormant Developmental Projects, 2010

LIST OF FIGURES

The Avicena Group, Inc. – Pipeline by Therapy Area and Indication, H2 2011
The Avicena Group, Inc. – Pipeline by Stage of Development, H2 2011
The Avicena Group, Inc. – Monotherapy Products in Pipeline, H2 2011 Skip to top